All posts by imreal

AltMed Florida to Open its 23rd MÜV™ Medical Cannabis Dispensary in the Fastest Growing community in the United States, Lakewood Ranch


We’re a homegrown privately owned Florida company that’s proud of our roots. We’re thrilled to be creating jobs and economic growth for communities across our state

AltMed Florida, one of the fastest growing MMTCs in the state (source: OMMU), continues its statewide expansion with a three-day opening, starting Monday June 29 at 10am for its newest MÜV™ Medical Cannabis Dispensary at 8465 Heritage Green Way, Bradenton, FL.

Opening in a busy retail plaza that houses a Crunch Fitness, MÜV’s first dispensary in Bradenton is easily accessible and highly visible off State Road 64 just east of Interstate-75.

AltMed Florida has continued to bring jobs and revitalization to Florida communities during the pandemic – more than doubling its dispensaries from 11 to 23 in 2020 alone.

“The more Floridians become aware of the benefits of medical cannabis the more inquiries we receive from people across the state asking when we’ll open a location in their area,” said Todd Beckwith, AltMed Director of Corporate Affairs. “We’re happy to answer the call and offer our wide range of premium products to residents of Bradenton and Lakewood Ranch. We’re also excited to bring new jobs to the Bradenton economy and help to drive business in the area.”

This MÜV™ Medical Cannabis Dispensary is the third to serve the greater Sarasota market joining dispensaries in on Fruitville Road in Sarasota and on the Tamiami Trail in North Port.

“Being able to bring our world class products to Bradenton is a win win for local patients. They will love what we offer and appreciate our incredibly helpful staff, and the modern, clean, streamlined aesthetic of our dispensaries,” said John Tipton, AltMed Florida CEO. “We’re a homegrown privately owned Florida company that’s proud of our roots. We’re thrilled to be creating jobs and economic growth for communities across our state.”

Deemed an essential service during the pandemic, AltMed Florida has been able to expand its workforce to over 500 employees with additional teams coming onboard at each of its 12 new dispensaries this year. With higher demand for products from 23 total dispensaries, AltMed has also generated additional construction employment and staffing with the expansion of its 220,000-square-foot cultivation facility in Apollo Beach.

During the Bradenton/Lakewood Ranch opening, staggered over three-days (June29-July1) for crowd mitigation, all licensed Florida medical cannabis patients will receive a one-time use only, one per patient, 25 percent off their entire first purchase. Patients are also encouraged to order at muvfl.com for express pickup or delivery to help reduce heavy traffic.

The newest state-of-the-art MÜV™ Lakewood Ranch dispensary will provide award-winning products to medical cannabis patients including an extensive selection of flower, pre-rolls, vaporizer pens, metered dose inhalers, topicals, oral sprays, patent-pending encapsulation formulations in its Tinctures, 72-Hour Transdermal patches and transdermal gels. MÜV also has one of the widest selections of concentrates for patients’ needing macro-dosing options.

Like AltMed Florida’s 22 other locations (Apollo Beach, Bonita Springs, Clearwater, Deerfield Beach, Fort Myers, Gainesville, Jacksonville/San Marco, Jacksonville Beach, Lady Lake, Lakeland, Longwood/Orlando, Lutz, North Port, Downtown Orlando, Ormond Beach, Pensacola, St.Petersburg, Sarasota, Sebastian, Tallahassee, Tampa and Wellington/West Palm), the new Lakewood Ranch MÜV dispensary stands out because it’s designed as a premium experience – think Apple Store, with a modern open-concept design and expert staff with extensive training.

The MÜV brand already has a wide following in other legal medical cannabis markets, including Arizona, where it has won five Best of Arizona medical cannabis awards. MÜV products are sold exclusively in Florida at MÜV dispensaries because, unlike other states, Florida does not allow wholesale of product between license holders – only products that license holders make themselves can be sold in their dispensaries.

For more information about the new ADA-compliant MÜV Medical Cannabis Dispensary in Bradenton/Lakewood Ranch, including hours and available MÜV products, visit muvfl.com.

AltMed Florida is on pace to open 40 MÜV Medical Cannabis Dispensaries across the state, all supplied by its 200,000-square-foot, state-of-the-art cultivation facility. Visit this link for images of AltMed Florida’s cultivation operations and watch this brief video to see what makes AltMed Florida and its MÜV™ Medical Cannabis Dispensaries stand out.

About Plants of Ruskin, LLC – d.b.a. AltMed Florida, LLC – With a focus on quality and attention to detail, Plants of Ruskin has more than 35 years of experience in providing seedlings to farmers for vegetable and medical product production. Plants of Ruskin founders, the Dickman Family, are 4th generation farmers with a long history of working in conjunction with the University of Florida, including an endowed chair specifically dedicated to plant improvement.

About AltMed Enterprises – Alternative Medical Enterprises, LLC, headquartered in Sarasota, FL and doing business as AltMed Enterprises, is a fully integrated medical cannabis company that brings compassion, community engagement and pharmaceutical industry precision to the development, production and dispensing of medical cannabinoids.

About MÜV™ – The MÜV brand of cannabis infused products was launched in Arizona in 2016 and quickly gained international attention and recognition. In its first six months alone, MÜV received four best of Arizona medical cannabis awards, including two first prizes for its proprietary Ethanol extractions that are the basis of all MÜV products.

Forward-Looking Statements – To the extent any statements made in this press release contain information that is not historical, these statements are forward-looking in nature and merely express our beliefs, expectations or opinions. For example, words such as “may,” “should,” “estimates,” “predicts,” “continues,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” “strategy” and similar expressions are intended to identify forward-looking statements. Such statements are based on current expectations or estimates and involve a number of known and unknown risks and uncertainties that could cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, the following: (i) our ability to implement our business strategy of distributing high quality cannabis products where permissible under applicable law; (ii) availability and cost of additional capital; (iii) our ability to attract, retain and motivate qualified employees and management; (iv) the impact of federal, state or local government regulations; (v) competition in the cannabis industry; (vi) our ability to generate revenues; and (vii) litigation in connection with our business. All forward-looking statements included in this press release and attributable to us or any person acting on our behalf are qualified by this cautionary statement. Forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.

Thriveworks Counseling Opens New Office in Fairfield, CT—Offers In-Person and Online Mental Health Services


Thriveworks Counseling is built on an important mission: to help people live happy, successful lives. The Thriveworks team is excited to offer mental health services at a new location in Fairfield, CT.

This counseling practice stands out from others in that it is committed to offering premium benefits that improve the client experience, including same and next-day appointments, online counseling opportunities, and innovative technologies like the Success Navigator which offers text support.

Certain obstacles might prevent an individual from scheduling or receiving counseling, such as a lack of availability or convenience. Thriveworks offers a solution to both of these problems by offering evening and weekend sessions in addition to daytime appointments throughout the week.

“People struggle to find providers who have availability during times that most working people are available, like evenings and weekends. Thriveworks addresses this problem and not only offers premium session times, but sets clients up with exceptional clinicians,” says Chief Compliance Officer at Thriveworks Heidi Faust.

Thriveworks Counseling sets people up with skilled, caring, and experienced counselors who are able to help their clients address specific challenges. Depression therapy, anxiety therapy, couples therapy, family therapy, and life coaching are but a few of the many services offered at Thriveworks Counseling.

About Thriveworks:

Thriveworks Counseling is dedicated to providing people with premium mental health care and also exceptional customer service. When an individual calls to set up a counseling session, they speak to a scheduling specialist who walks them through the quick and easy process.

Thriveworks Counseling pairs individuals with skilled, caring mental health professionals who have a wide range of skills, training, and experience. To schedule a session or find more information about Thriveworks in Fairfield, call (203) 433-3563 or visit https://thriveworks.com/fairfield-counseling/

Share article on social media or email:

Albert Einstone’s (AE) Partners With Leading Cannabis Sales and Distribution Platform Kiva Sales and Service (KSS)


Albert Einstone’s has carved a path in cannabis that is consumer-centric while maintaining an appetite for innovation across different categories. Their attention to detail in product generation ensures an extremely high quality and allows them to separate from others in this competitive industry.

Albert Einstone’s (AE), the California-based Cannabis manufacturing, cultivation and distribution company responsible for the brands El Blunto and Simply Stoneade, announced an exclusive distribution partnership with Kiva Sales and Service (KSS), the states’ leading distribution operator.

“Albert Einstone’s has carved a path in cannabis that is consumer-centric while maintaining an appetite for innovation across different categories. Their attention to detail in product generation ensures an extremely high quality and allows them to separate from others in this highly competitive industry.” said Brian Dewey, VP of Sales at KSS. “We are excited about their complimentary portfolio and look forward utilizing our leading distribution platform to extend their vision into the market and drive customer adoption.”

The KSS alliance will mark AE’s first exclusive distribution partnership. The agreement between these two iconic California cannabis brands will expand KSS’s lavish portfolio of premium products and is projected to more than double AE’s retail availability.

The Oakland-based Kiva Sales and Service will start shipping Albert Einstone’s full portfolio of top-shelf cannabis products to licensed dispensaries in California effective immediately. KSS’s logistic capabilities will increase AE’s speed to market and meet the consistently rising demand from California consumers for AE’s products.

“Kiva shares our commitment to creating the ideal consumer experience, developing lasting brand loyalty, and building a community. We are delighted to partner with a distributor that is as established, well-regarded, and creative as KSS. We look forward to working closely with Kiva to elevate the California cannabis experience and take it to the next level.” said Q Ladraa, Albert Einstone’s Chief Executive Officer.

The partnership further establishes Kiva Sales and Service as the industry-leading sales and distribution company, offering cannabis dispensaries a comprehensive portfolio of brands across multiple categories.

About Albert Einstone’s

Albert Einstone’s (AE) is a California-based distribution, cultivation and manufacturing company that produces, develops and distributes products. AE delivers a completely controlled, vertically integrated marijuana experience. Product design and development is approached like a true science, ensuring customers get the same, phenomenal experience every single time. Equipped with a state-of-the-art organic, indoor cultivation facility, manufacturing lab and expansive distribution network, AE establishes a new standard in the cannabis space. AE’s two initial product lines, El Blunto and Simply Stoneade, have been broadly celebrated and are available throughout California. For more information, visit http://www.alberteinstones.com Follow us on instagram @Alberteinstones @Elblunto.ca @Simplystoneade

About Kiva Sales & Service

In 2010 we at Kiva made a commitment to never release a product to our customer until it was perfect. We used that same philosophy as our driving mission at Kiva Sales & Service to make sure we provide the best customer service of any distributor in the market. Our goal is to build the leading distributor for premium California cannabis brands with a strong focus on service, brand building, and relationships that will accelerate growth for all our partners executed by a single distributor for all of your California strategy. With our commitment to dispensary service and a curated portfolio of industry leading cannabis brands, we can be stronger together. For more information, visit https://kivaconfections.com/. Follow us on instagram @madebykiva

Share article on social media or email:

Making Educated and Informed Choices to Stay Sun-Safe


Dr. Allison Britt Kimmins

“In spite of all we know,” notes Dr. Britt Kimmins, “rates of skin cancer continue to rise.”

As never before, the chance to get outside under sunny skies is a relief. “It’s been especially welcoming as a result of the COVID-19 Pandemic,” observes Dr. Allison Britt Kimmins, a dermatologist with Advanced Dermatology PC. After weeks spent inside to limit the spread of coronavirus, it is no surprise that we are all anxious to get outside and enjoy the sun. “However” emphasizes Dr. Britt Kimmins, “we want to make sure that we also protect ourselves from the damaging and potentially deadly ultraviolet light.”

Skin cancer is the most common cancer in the world. In the United States, cases outnumber all other cancers combined, according to the non-profit Skin Cancer Foundation.

“In spite of all we know,” notes Dr. Britt Kimmins, “rates of skin cancer continue to rise. In this country, 20% of the population will get skin cancer by the time we’re seventy. Last year, it was estimated that 192,310 people in the U.S. would be diagnosed with melanoma – the deadliest cancer of all.”

The threat of the sun’s ultraviolet rays is so great that the World Health Organization lists them as Group 1 carcinogens, alongside plutonium and cigarettes. The U.S. Department of Health and Human Services also has labeled the sun’s radiation as a known carcinogen. “Ninety percent or more of cases of skin cancer are linked to sun exposure,” states Dr. Britt Kimmins. According to the Skin Cancer Foundation, “having 5 or more sunburns doubles your risk of developing melanoma.” In 2020, it is estimated that the number of melanoma cases is expected to rise.

“Every one of us – regardless of skin tone or age – will benefit from practicing ‘safe sun precautions,’” advises Dr. Britt Kimmins, who makes the following suggestions to enjoy the outdoors safely.

5 Tips to Stay Sun-Safe This Summer – and Year-Round

1. Stick to your skin-checkup schedule: “Early intervention is essential to stay safe from skin cancer. “When detected and treated early, the 5 year survival rate for melanoma is over 98%. Dr. Britt Kimmins recommends that patients see a dermatologist to establish their baseline level of skin health and identify their level of risk. Scheduling regular annual skin examinations will help to monitor the skin for changes and encourage self-examination. This supports early intervention and effective treatment.”

2. Make sure that your sunscreen protects you: “People may think they’re protected when they are not,” warns Dr. Britt Kimmins. “We need to apply enough sunscreen at least 15 minutes before going outdoors and reapply every 2 hours while outside. If swimming or sweating, more frequent reapplication may be necessary. It is important to apply enough sunscreen to all exposed areas including hands, feet, neck, scalp and ears. A one ounce shot glass is the amount needed to cover exposed areas of skin.

3. Remember: You need more than sunscreen: “Even if we follow the American Academy of Dermatology’s guidelines,” notes Dr. Britt Kimmins, “and use a water-resistant product that is SPF 30 or higher with full-spectrum UVA/UVB protection, we cannot completely avoid the sun’s rays. Between 10 a.m. and 2 p.m., when the sun is most direct, we need to be careful: Seek shade and wear protective clothing, including a hat and sunglasses.”

4. Indoor ‘sun’ is just as risky: “Just one indoor tanning session,” Dr. Britt Kimmins emphasizes, “can increase the risk of cancer by almost 70%. Additionally, tanning beds primarily emit UVA rays which penetrate our skin more deeply, further accelerating changes associated with aging.”

5. Pass safe sun habits on to the next generation: “Protecting children and helping young people develop healthy sun habits are keys to reducing skin cancer rates, “states Dr. Britt Kimmins. Just one blistering sunburn during childhood almost doubles the risk of melanoma. Most of the damage occurs before the age of eighteen. Young people are influenced by the behaviors of their caregivers. We see this, for example, with tanning bed use, which often begins during teen years, in the company of a family member.”

“As we all spend time outdoors this summer, “let’s remember our sun-safety suggestions so we can stay healthy now – and skin-cancer-free for years to come.”    

Bio: Allison Britt Kimmins, MD, MPH, is board-certified in dermatology.

Advanced Dermatology P.C. and the Center for Laser and Cosmetic Surgery (New York, New Jersey & PA) is one of the leading dermatology centers in the nation, offering highly experienced physicians in the fields of cosmetic and laser dermatology as well as plastic surgery and state-of-the-art medical technologies. http://www.advanceddermatologypc.com.

Share article on social media or email:

ERT Continues to Drive Innovation in Virtualization for Respiratory Clinical Trials


ERT is innovating clinical trial virtualization through its partnership with Inofab Health, makers of Spirohome, the world’s first ultrasonic personal spirometer.

“This partnership enables ERT to further drive innovation in trial virtualization and supports our commitment to offering the best range of trial continuity options, specifically for sponsors developing new respiratory disease treatments.” – Achim Schülke, EVP Respiratory, ERT.

ERT, the global leader in clinical endpoints data collection, today announced a strategic partnership with Inofab Health, a healthcare technology company designing and developing ultrasonic spirometry technology for in-clinic and at-home use. Through the partnership, ERT expands its portfolio of innovative virtual trial solutions to give clinical trial sponsors and contract research organizations (CROs) multiple options for continuing their life-saving research throughout the pandemic and beyond.

Sponsors are looking for reliable data collection methods that enable the continuation of important clinical trials and ensure the safety of clinical trial patients, without requiring them to attend investigative site appointments. ERT is meeting this need with a suite of innovative virtual trial solutions that capture high-quality data from the comfort of patients’ homes.

“We chose to partner with Inofab based on their proven capabilities in meeting respiratory patients’ healthcare needs and their award-winning ultrasonic spirometer, Spirohome,” said Achim Schülke, Executive Vice President of Respiratory Solutions at ERT. “This partnership enables ERT to further drive innovation in trial virtualization and supports our commitment to offering the best range of trial continuity options, specifically for sponsors developing new respiratory disease treatments.”

Since patients with lung disease are at higher risk for developing more serious complications from the COVID-19 illness, many are likely to avoid clinics or investigative sites to minimize their exposure risk. Together, ERT and Inofab will continue to develop patient-friendly, easy to use solutions enabling at-home, patient-administered testing of the lung, supporting patient comfort and safety while ensuring high-quality data collection to keep respiratory trials on track.

“We’re pleased to partner with ERT and to leverage their extensive experience in delivering the important safety and efficacy data sponsors need when developing new respiratory treatments,” said Kerem Yasar, Chief Technology Officer and Co-Founder of Inofab Health. “Spirohome plays a critical role for endpoint data collection and we’re excited to work with ERT in delivering virtual trial solutions that help clinical trial sponsors continue developing new treatments for the millions of patients living with respiratory disease.”

For more information on ERT’s suite of virtual trial solutions, visit virtualtrials.ert.com.

About ERT

ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.

Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2019, 75% of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs, and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.

For more information, go to ert.com or follow us on LinkedIn and Twitter.

About Inofab Health

Inofab Health offers revolutionizing respiratory care solutions for home and professional use with a human-centric approach and cutting-edge technology. It provides a functional respiratory care management platform along with ultrasonic personal & clinic spirometers and connected inhaler attachments. Inofab Health alerts any declines in lung health, allowing quick intervention against symptom onset and prevents unnecessary hospitalisations.

For further information see https://Inofab.health.

Share article on social media or email:



Genedata Aids Merus in Development of Precision Immunotherapies


News Image

We look forward to utilizing Genedata Profiler and Genedata Managed IT Services to assist us in our mission to develop safe, targeted, effective therapeutics for cancer patients

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that it has entered into a multi-year contract with Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Multiclonics®), to support their translational and clinical research strategy to discover and develop ground-breaking drugs. The agreement includes a software license to the Genedata Profiler® platform as well as a variety of service arrangements, including consulting services and Managed IT Services, a recently added offering to the Genedata Service Portfolio.

Under the terms of the agreement, Genedata is committed to maintaining full operational responsibility for the software. In addition, Genedata has agreed to provide consulting services for workflow setup, data integration, and user training to get Merus productive with Genedata Profiler quickly and efficiently.

“Our unique technology uses large-scale functional screening in molecular and cell-based assays to identify unique oncology therapeutic multispecific antibody candidates from among thousands tested against an array of targets,” said John de Kruif, Ph.D., Chief Technology Officer of Merus. “We have long understood and valued the importance of being able to collect and analyze complex data sets in order to optimize the discovery of new combinations and modes of action. As we expect our clinical and pre-clinical programs and pipeline to continue to grow, we look forward to utilizing Genedata Profiler and Genedata Managed IT Services to assist us in our mission to develop safe, targeted, effective therapeutics for cancer patients.”

Genedata Profiler permits Merus’ scientists to leverage all the data and knowledge from past, current and future preclinical experiments and clinical trials, facilitating efficient translational and reverse translational research. It fosters secure collaboration between internal and external research groups and empowers users to make data-informed decisions with powerful, well-engineered analytical tools. Genedata Profiler depicts and tracks the whole data life cycle in a secure way with easy-to-use, fully configurable workflows, straight out of the box.

“We are excited to add Merus, a leading innovator in the oncology and multispecific antibody space, to our rapidly growing list of biopharmaceutical companies that have recognized the value that Genedata Profiler can bring to their translational and clinical research programs”, said Othmar Pfannes, Ph.D., CEO of Genedata. “With the expansion of our services portfolio to include Managed IT Services, we also demonstrate our commitment to medium sized biopharmaceutical companies who are looking for an all-in-one service provider. We remain committed to supporting our customers in making their R&D processes more efficient and scalable.”

About Genedata

Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.

http://www.genedata.com

LinkedIn | Twitter | YouTube

Contact

Miles Fisher-Pollard

Genedata

Public Relations

Phone: +41 61 511 85 61

pr@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:



Source Molecular Adds Environmental SARS-CoV-2 Testing Under A2LA Scope


News Image

“SMC’s A2LA accreditation for our suite of COVID-19 services is yet another example of our company’s innovative approach to pathogen and molecular source tracking.” – Anda Quintero, SMC’s Laboratory Scientific Director

On May 21st, the A2LA-accredited laboratory Source Molecular Corporation (SMC) introduced testing services for SARS-CoV-2, the virus that causes COVID-19, on wastewater, air, and surfaces. They are the first A2LA-accredited laboratory to conduct this type of SARS-CoV-2 testing, which is covered by their flexible scope of accreditation. SMC, a Florida-based molecular testing lab, provides innovative technology to help solve pathogenic water, air and surface pollution problems through source tracking, genetic and molecular techniques, and test kits. These new tests, developed to help address the spread of coronavirus, are a timely complement to their longstanding mission. A2LA updated SMC’s scope in 2019 when their accreditation was renewed, which enabled them to add these new tests in response to the ongoing global pandemic.

By providing a suite of commercial COVID-19 environmental testing supplies and services, SMC assists clients with identification, data interpretation, solution strategies and continued virus monitoring for private and public sectors including hospitality, travel, agriculture, medical services, utilities, wastewater and large government agencies. SMC has been accredited by A2LA since 2017 and throughout the years their in-house laboratory has analyzed samples for hundreds of industrial plants, watershed management groups, government agencies, universities, and engineering firms. SMC is one of the global leaders in both Pathogenic Source Tracking (PST) and Microbial Source Tracking (MST). With a broad range of new tests and testing methods being developed in response to COVID-19, third-party accreditation by A2LA helps to ensure that the organizations developing these tests are competent and that their test results are produced with reliable and consistent methods.

“SMC’s A2LA accreditation for our suite of COVID-19 services is yet another example of our company’s innovative approach to pathogen and molecular source tracking.” Says Anda Quintero, SMC’s Laboratory Scientific Director. “From the beginning, accreditation by A2LA to ISO 17025:2005 helped us build a strong foundation for our top-quality services in the MST field. We updated our fixed scope to flexible scope last year to ISO 17025:2017 during our renewal of accreditation. The flexible scope allows us to take swift steps to respond to public health emergencies, such as COVID-19 environmental testing, in a way that we can best serve our clients in the time they most needed, without sacrificing the quality of our work. Therefore, we are always grateful to work with A2LA.”

About Source Molecular Corporation

Source Molecular is a US-based provider of molecular testing, pathogenic source tracking, microbial source tracking, and related consultation services founded in 2002. To learn more about them visit sourcemolecular.com.

About A2LA

A2LA is a non-profit, non-governmental, third-party accreditation body, offering internationally recognized accreditation services to testing and calibration laboratories, sampling organizations, inspection bodies, proficiency testing providers, reference material producers, biobanking facilities, and product certifiers. To learn more, visit A2LA.org.

Share article on social media or email:

Demystifying Decentralized Clinical Trials and Enabling Your Study for Success, Upcoming Webinar Hosted by Xtalks


Xtalks Life Science Webinars

Join this educational webinar to learn how CROs and Pharma can fast track plans for decentralized clinical trials with the smart capabilities of the Internet of Things (IoT).

Join Bryan Lubel, Executive Vice President at IoT Managed Services at KORE and Rust Felix, Co-Founder & CEO of Slope.io, Inc in a live session on Tuesday, July 14, 2020 at 1pm EDT.

Decentralizing clinical trials is no longer a ‘nice-to-have’ feature to reduce clinical trial times and improve participant engagement. The COVID-19 outbreak has shattered this illusion and placed the spotlight on the imperative to have better, faster access to new drugs, meaning clinical trials can no longer languish in a tedious, paper-based approach. According to the US National Library of Medicine’s ClincialTrials.gov site, there are over 55,000 clinical trials actively enrolling participants worldwide right now.

Join this educational webinar to learn how CROs and Pharma can fast track plans for decentralized clinical trials with the smart capabilities of the Internet of Things (IoT). With the enablement of IoT, participants are no longer required to appear in-person for physician visits, and valuable clinical data can be gathered remotely. This sounds very streamlined, but in fact over 76 percent of all IoT projects fail, resulting in further delays and the loss of countless dollars.

In this webinar, the presenters will talk about the common mistakes companies make when trying to decentralize their clinical trials. They will also discuss how to increase participant engagement & satisfaction, as well as manage the full spectrum of decentralized clinical trials from conception to completion with cost saving tactics.

For more information or to register for this event, visit Demystifying Decentralized Clinical Trials and Enabling Your Study for Success.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

How Multispectral Imaging Enables Analysis of Macrophages in Chronic Liver Disease, Upcoming Webinar Hosted by Xtalks


Xtalks Life Science Webinars

Spectral imaging microscopy and deep-learning-based image analysis was applied and found to be a powerful tool that enables in situ analysis of macrophage phenotypes and other cells in human liver biopsies and may lead to more personalized therapeutic approaches in the future.

Join Heather Stevenson, MD, PhD, Associate Professor, Dept. of Pathology and Director of Transplantation Pathology at The University of Texas Medical Branch in a live session on Tuesday, July 14, 2020 at 11am EDT (4pm BST/UK).

Intrahepatic macrophages influence the composition of the microenvironment, host immune response to liver injury and development of fibrosis. Using a multiplex protocol, Dr. Stevenson’s group stained biopsies collected from representative patients with chronic liver diseases, including chronic hepatitis C, non-alcoholic steatohepatitis and autoimmune hepatitis. Spectral imaging microscopy and deep-learning-based image analysis was applied and found to be a powerful tool that enables in situ analysis of macrophage phenotypes and other cells in human liver biopsies and may lead to more personalized therapeutic approaches in the future.

In the webinar, Dr. Stevenson will present her group’s findings from an analysis of five different antibodies commonly observed on macrophage populations (CD68, MAC387, CD163, CD14 and CD16).

For more information or to register for this event, visit How Multispectral Imaging Enables Analysis of Macrophages in Chronic Liver Disease.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

NFP Creates Cost Impact Modeling Tool to Address Projected Benefit Costs Associated with COVID-19


News Image

“We remain focused on aligning the challenges clients face with effective solutions and tools like our COVID-19 Cost Impact Model,” said Kim Bell.

NFP, a leading insurance broker and consultant that provides property and casualty (P&C), corporate benefits, retirement and individual solutions, today introduced its COVID-19 Cost Impact Model. The model is a dynamic tool designed to support employers as they assess the effects of the pandemic on their benefit costs and make decisions on potential plan adjustments that align with their overall benefits strategy.

The NFP COVID-19 Cost Impact Model uses proprietary situation modeling to project future infections, testing, diagnosis and treatment. Through a comparison of an established baseline of testing and positive infection rates in a client’s state and country, the model can project estimated costs. The modeling scenarios address testing and treatment costs for up to 180 days to ensure reliable projections. NFP will update the model as new information and data surrounding COVID-19 becomes available, ensuring projections reflect the application of the most relevant information. Refining the projections with the latest data will help clients enhance their ability to prepare for the remainder of this pandemic and make informed financial decisions for future needs.

“COVID-19 has created many challenges for employers and we’re excited to support our clients with data-driven solutions that help them estimate costs and inform actions,” said Kim Bell, NFP’s senior vice president, head of health and benefits. “We remain focused on aligning the challenges clients face with effective solutions and tools like our COVID-19 Cost Impact Model.”

In partnership with Milliman, NFP has also developed MedFactor, a proprietary plan value modeling tool. This internal resource allows NFP to estimate the relative value of plan design changes. By entering a client’s base plan features and contrasting those features with a proposed alternative, NFP can calculate the percentage change in actuarial value. This provides employers with valuable insight on the impact of proposed changes and confidence in making complex decisions.

“In an environment with so much uncertainty, there is tremendous value in tools that use data to help guide us to the right decisions,” said NFP chairman and CEO Doug Hammond. “We will continue to commit resources to developing tools and expertise that help our clients solve problems and plan for the future.”

About NFP

NFP is a leading insurance broker and consultant providing specialized property and casualty, corporate benefits, retirement and individual solutions through its licensed subsidiaries and affiliates. NFP enables client success through the expertise of over 5,600 global employees, investments in innovative technologies, and enduring relationships with highly rated insurers, vendors, and financial institutions. NFP is the 5th largest benefits broker by global revenue, 6th largest US-based privately owned broker, and 8th best place to work in insurance (Business Insurance); 10th largest property and casualty agency (Insurance Journal); and 13th largest global insurance broker (Best’s Review).

Visit NFP.com to discover how NFP empowers clients to meet their goals.

Share article on social media or email: